Japanese study involving Athersys’ MultiStem technology has enrolled its first patient

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Cleveland biotechnology company Athersys Inc. (Nasdaq: ATHX) announced that Healios K.K., its partner in Japan, has enrolled the first patient in a study evaluating MultiStem cell therapy treatment of patients who have suffered an ischemic stroke.

Athersys said in a Nov. 15 news release that the Healios study, known as TREASURE., is designed to enroll a total of 220 patients with moderate to severe strokes.

Click here to read the complete article.

Originally published November 16, 2017.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: